U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689058) titled 'CAR-T in Relapsed/Refractory Multiple Myeloma' on June 27.
Brief Summary: The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome...